These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3988351)

  • 1. Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.
    Drusano GL; de Jongh C; Newman K; Joshi J; Wharton R; Moody MR; Schimpff SC
    Infection; 1985; 13(1):20-6. PubMed ID: 3988351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.
    Winston DJ; Barnes RC; Ho WG; Young LS; Champlin RE; Gale RP
    Am J Med; 1984 Sep; 77(3):442-50. PubMed ID: 6475984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
    Finley RS; Fortner CL; deJongh CA; Wade JC; Newman KA; Caplan E; Britten J; Wiernik PH; Schimpff SC
    Antimicrob Agents Chemother; 1982 Aug; 22(2):193-7. PubMed ID: 6765414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin.
    De Jongh CA; Wade JC; Schimpff SC; Newman KA; Finley RS; Salvatore PC; Moody MR; Standiford HC; Fortner CL; Wiernik PH
    Am J Med; 1982 Jul; 73(1):89-96. PubMed ID: 6211981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
    Wade JC; Standiford HC; Drusano GL; Johnson DE; Moody MR; Bustamante CI; Joshi JH; deJongh C; Schimpff SC
    Am J Med; 1985 Jun; 78(6A):62-72. PubMed ID: 3859217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
    Standiford HC; Drusano GL; Bustamante CI; Rivera G; Forrest A; Tatem B; Leslie J; Moody M
    Antimicrob Agents Chemother; 1986 Mar; 29(3):412-7. PubMed ID: 3459390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative trial of moxalactam plus ticarcillin and clavulanic acid or piperacillin as empiric antibiotic therapy for febrile cancer patients.
    D'Olimpio JT; Miller M; Sheridan CA; Carlisle P; Wollner DI; McKitrick JC; Wiernik PH
    J Clin Pharmacol; 1987 Sep; 27(9):673-7. PubMed ID: 3316311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.
    Winston DJ; Ho WG; Bruckner DA; Gale RP; Champlin RE
    Am J Med; 1988 Jul; 85(1A):21-30. PubMed ID: 3041815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serum bactericidal activity of latamoxef (moxalactam), cefoperazone and cefotaxime.
    McNamee W; Drusano GL; Tatem BA; Standiford HC
    J Antimicrob Chemother; 1984 Nov; 14(5):491-7. PubMed ID: 6096348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cefmenoxime or piperacillin plus amikacin. A prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients].
    Sampi K; Kumai R; Maseki N; Sakurai M; Kaneko Y; Hattori M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):674-9. PubMed ID: 3469935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group.
    Meunier F; Zinner SH; Gaya H; Calandra T; Viscoli C; Klastersky J; Glauser M
    Antimicrob Agents Chemother; 1991 May; 35(5):873-8. PubMed ID: 1854169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Rizal AM; Nordiah AJ; Jamal R
    Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients.
    Jones P; Rolston K; Fainstein V; Elting L; Bodey GP
    Rev Infect Dis; 1985; 7 Suppl 4():S741-6. PubMed ID: 3909332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.
    Drusano GL; Standiford HC; Fitzpatrick B; Leslie J; Tangtatsawasdi P; Ryan P; Tatem B; Moody MR; Schimpff SC
    Antimicrob Agents Chemother; 1984 Sep; 26(3):388-93. PubMed ID: 6391372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.